FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 794 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer MOST POPULAR Woman Creates Non-Toxic Nail Polish Brand After Her Mom’s Breast Cancer... November 20, 2020 Black In Cancer – That Cancer Conversation October 8, 2021 Using Integrative Therapies to Help Manage Cancer-Related Pain: An Expert Q&A July 20, 2023 Judge Rules That 3-Year-Old Child With Leukemia Must Get Chemo Against... May 16, 2019 Load more HOT NEWS ESMO Congress 2023, 20-24 October 2023 Madrid, Spain Wistful Facebook Comment Sends Volunteers Flocking To Help MS Patient Fulfill... First-Line Treatment with Pembrolizumab-Chemotherapy Results in Longer OS than Chemotherapy Alone... FDA Amends Indication for Pembrolizumab in the First-Line Treatment for Patients...
